https://www.selleckchem.com/pr....oducts/Rapamycin.htm
To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) treat-and-extend dosing in patients with macular edema secondary to central retinal vein occlusion (CRVO). CENTERA (Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO; NCT02800642) was an open-label, Phase 4 clinical study. Patients received 2 mg of IVT-AFL at baseline and every 4weeks thereafter, until disease stability criteria were met (or until week 2, at which point treatment intervals were adjusted in
Like
Comment
Share
